Subspecialty	Cardiology
Clinical Interests	Cardiovascular Disease
	Congestive Heart Failure
	Coronary Artery Disease
	Heart Disease & Women
	Heart Failure
	Heart Transplant
Gender	Female
E-mail	jill.kalman@mountsinai.org
Education and Training	MD, Mount Sinai School of Medicine
	Residency, Internal Medicine, Mount Sinai Hospital
	Fellowship, Cardiology, Mount Sinai Hospital

Dr. Jill Kalman is the Director of the Cardiomyopathy Program at Mount Sinai Medical Center.  She is an expert in the field of Congestive Heart Failure and is extensively published in this area.  Her primary focus in clinical investigation in heart failure focuses on novel medical therapies, technologies and device therapy in all stages of heart failure.  She began in the specialty of Heart Failure at Mount Sinai, and then started and developed the Heart Failure Program at Beth Israel Medical Center from 1998-2005.  She was subsequently recruited to New York University Medical Center as Director of the Cardiomyopathy Program and Chief of the Cardiac Service of Tisch Hospital.  In 2007, she was recruited back to Mount Sinai as the Director of the Program to further develop and expand the Heart Failure and Transplant Program.

Dr. Kalman graduated from the University of Pennsylvania with honors and received her medical degree from the Mount Sinai School of Medicine.  She has been dedicated to Mount Sinai, and completed her internal medicine residency and cardiology fellowship at the Mount Sinai Medical Center, including a research fellowship in heart failure and cardiac transplantation. 

Dr. Kalman has dedicated her career to improving the quality and quantity of life in patients with all stages of Heart Failure.

Education and Training	MD, Mount Sinai School of Medicine
	Residency, Internal Medicine, Mount Sinai Hospital
	Fellowship, Cardiology, Mount Sinai Hospital

Subspecialty	Cardiology
Clinical Interests	Cardiovascular Disease
	Congestive Heart Failure
	Coronary Artery Disease
	Heart Disease & Women
	Heart Failure
	Heart Transplant

Neelagaru SB, Sanchez JE, Lau SK, Greenberg SM, Raval NY, Worley S, Nadamanee K, Merliss AD, Krueger S, Wood M, Wish M, Burkhoff D, Kalman J. Nonexcitatory, cardiac contractility modulation (CCM) electrical impulses: feasibility study for advanced heart failure in patients with normal QRS duration. Heart Rhythm 2006;.

Galvao M, Kalman J, Demarco T, Moskowitz R, Galvin C, Ghali J, Fonarow G. Gender Differences iospital Management and Outcomes in Patients with Decompensated Heart Failure: Analysis from the Acute Decompensated Heart Failure National Registry (ADHERE In-H. Journal of Cardiac Failure 2005;.

Mitchell J, Klapholz M, Meisner J, Kalman J, Steingart R, Sehhat K, LeJemtel T, Messineo F, Maurer M, Phillips R, Brown E, Katz S, Sleeper L, Varshneya N. Therapeutic Management of Patients Hospitalized for Heart Failure with Normal Systolic Function: Results of the New York Heart Failure Consortium Registry on Diastolic Dysfunction. J Am Coll Cardiol 2004; 43: 1432-1438.

Kukin ML, Mannino MM, Ocampo ON, Kalman J, Buchholz-Varley C, Freudenberger RS. Hemodynamic Comparison of Twice Daily Metoprolol Tartrate With Once Daily Metoprolol Succinate in Congestive Heart Failure. J Am Coll Cardiol 2000; 35: 45-50.

Kukin ML, Kalman J, Charney RH, Eng C, Buchholz-Varley C, Ocampo ON, Levy DK. Prospective, Randomized Comparison of Effect of Long-Term Treatment With Metoprolol or Carvedilol on Symptoms, Exercise, Ejection Fraction, and Oxidative Stress in Heart Failure. Circulation 1999; 99: 2645-2651.

Freudenberger R, Kalman J, Kukin M, Buhholz-Varley C, Ocampo O, Mannino MM. Effect of Race in the Response to Metoprolol in Patients with Congestive Heart Failure Secondary to Idiopathic Dilated or Ischemic Cardiomyopathy . 1997;.

Kukin ML, Kalman J, Ocampo O, Freudenberger R, Buchholz C, Mannino MM. Beta Blockade in Congestive Heart Failure. Persistent Adverse Haemodynamic Effects During Chronic Therapy with Subsequent Doses. Heart 1997; 78: 444-449.

Kukin ML, Kalman J, Ocampo O, Freudenberger R, Buchholz C, Mannino MM. Combined Alpha-Beta Blockade compared to Beta Blockade Alone in Congestive Heart Failure. Am J Cardiol 1996; 77: 486-491.

Kalman J, Buchholz C, Steinmetz M, Kukin ML, Gass A, Lansman S, Courtney M. Safety and efficacy of beta blockade in patients with chronic congestive heart failure awaiting heart transplant. J Heart and Lung Transplantation 1995; 14: 1212-1217.

Levine B, Kalman J, Packer M, Fillet H, Mayer L. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. New England Journal of Medicine 1990; 323: 236-241.